J Remon1, D Alvarez-Berdugo2, M Majem3, T Moran4, N Reguart5, P Lianes6. 1. Medical Oncology Department, Hospital de Mataró, Carretera de la Cirera, s/n, 08304, Mataró, Barcelona, Spain. jremon@csdm.cat. 2. Laboratorio de Motilidad Digestiva CIBERehd, Hospital de Mataró, Carretera de la Cirera, s/n, 08304, Mataró, Barcelona, Spain. dalvarezbe@csdm.cat. 3. Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret, 167, 08025, Barcelona, Spain. mmajem@santpau.cat. 4. Medical Oncology Department, Institut Català d'Oncologia -Badalona, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain. mmoran@iconcologia.net. 5. Medical Oncology Department, Hospital Clinic de Barcelona, Villarroel 170, 08036, Barcelona, Spain. nreguart@clinic.ub.es. 6. Medical Oncology Department, Hospital de Mataró, Carretera de la Cirera, s/n, 08304, Mataró, Barcelona, Spain. plianes@csdm.cat.
Abstract
INTRODUCTION: The prognostic value of EGFR mutation in lung cancer patients with brain metastases is uncertain and therapeutic efficacy with EGFR TKI is limited. Looking for biomarkers closely related with early tumor changes and brain metastases in non-small cell lung cancer is warranted. MicroRNAs (miRNAs) are frequently deregulated in lung cancer. The objective of this study was to investigate whether some miRNAs are related with brain metastasis risk in EGFR-mutant non-small cell lung cancer patients. MATERIALS AND METHODS: miRNA quantification was retrospectively performed in formalin-fixed, extracranial paraffin-embedded adenocarcinoma tumor tissue available from 17 human samples of advanced non-small cell lung cancer patients. Samples were classified as brain metastasis group (5 EGFR-mutant patients with initial BM, EGFRm-BM+; and 6 EGFR wild-type patients with initial BM) and the control group (6 EGFR-mutant NSCLC patients without BM). The RNA obtained was preamplified and retro-transcribed, and the miRNA was quantified with the TaqMan OpenArray Human MiRNA Panel in the QuantStudio™ 12 K Flex Real-Time PCR system. RESULTS: miRNA-197 and miRNA-184 showed a significant higher expression in EGFRm-BM+ group than in the control group (p = 0.017 and p = 0.01, for miRNA-197 and miRNA-184, respectively), with a trend toward overexpression in BM group compared with the control group (p = 0.08 and p = 0.065, for miRNA-197 and miRNA-184, respectively), without differences in expression in BM group according to EGFR mutational status (EGFR wild type vs. EGFR-mutant: p = 0.175 and p = 0.117, for miRNA-197, miRNA-184 respectively). CONCLUSIONS: miRNA-197 and miRNA-184 are overexpressed in EGFR-mutant patients with BM and they might be a new biomarker for stratifying the risk of BM in this subpopulation.
INTRODUCTION: The prognostic value of EGFR mutation in lung cancerpatients with brain metastases is uncertain and therapeutic efficacy with EGFR TKI is limited. Looking for biomarkers closely related with early tumor changes and brain metastases in non-small cell lung cancer is warranted. MicroRNAs (miRNAs) are frequently deregulated in lung cancer. The objective of this study was to investigate whether some miRNAs are related with brain metastasis risk in EGFR-mutant non-small cell lung cancerpatients. MATERIALS AND METHODS: miRNA quantification was retrospectively performed in formalin-fixed, extracranial paraffin-embedded adenocarcinoma tumor tissue available from 17 human samples of advanced non-small cell lung cancerpatients. Samples were classified as brain metastasis group (5 EGFR-mutant patients with initial BM, EGFRm-BM+; and 6 EGFR wild-type patients with initial BM) and the control group (6 EGFR-mutant NSCLCpatients without BM). The RNA obtained was preamplified and retro-transcribed, and the miRNA was quantified with the TaqMan OpenArray Human MiRNA Panel in the QuantStudio™ 12 K Flex Real-Time PCR system. RESULTS:miRNA-197 and miRNA-184 showed a significant higher expression in EGFRm-BM+ group than in the control group (p = 0.017 and p = 0.01, for miRNA-197 and miRNA-184, respectively), with a trend toward overexpression in BM group compared with the control group (p = 0.08 and p = 0.065, for miRNA-197 and miRNA-184, respectively), without differences in expression in BM group according to EGFR mutational status (EGFR wild type vs. EGFR-mutant: p = 0.175 and p = 0.117, for miRNA-197, miRNA-184 respectively). CONCLUSIONS:miRNA-197 and miRNA-184 are overexpressed in EGFR-mutant patients with BM and they might be a new biomarker for stratifying the risk of BM in this subpopulation.
Authors: R Porta; J M Sánchez-Torres; L Paz-Ares; B Massutí; N Reguart; C Mayo; P Lianes; C Queralt; V Guillem; P Salinas; S Catot; D Isla; A Pradas; A Gúrpide; J de Castro; E Polo; T Puig; M Tarón; R Colomer; R Rosell Journal: Eur Respir J Date: 2010-07-01 Impact factor: 16.671
Authors: Stephanie Heon; Beow Y Yeap; Neal I Lindeman; Victoria A Joshi; Mohit Butaney; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson Journal: Clin Cancer Res Date: 2012-06-25 Impact factor: 12.531
Authors: Antonio M P Omuro; Mark G Kris; Vincent A Miller; Enrico Franceschi; Neelam Shah; Daniel T Milton; Lauren E Abrey Journal: Cancer Date: 2005-06-01 Impact factor: 6.860
Authors: Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2009-07-21 Impact factor: 12.531
Authors: Wang-Xia Wang; Robert J Danaher; Craig S Miller; Joseph R Berger; Vega G Nubia; Bernard S Wilfred; Janna H Neltner; Christopher M Norris; Peter T Nelson Journal: Genomics Proteomics Bioinformatics Date: 2014-01-28 Impact factor: 7.691
Authors: Petra Hoffknecht; Amanda Tufman; Thomas Wehler; Theo Pelzer; Rainer Wiewrodt; Martin Schütz; Monika Serke; Jan Stöhlmacher-Williams; Angela Märten; Rudolf Maria Huber; Nicolas J Dickgreber Journal: J Thorac Oncol Date: 2015-01 Impact factor: 15.609
Authors: Brent Earl Schultz; Christopher R Spock; Laura K Tom; Yong Kong; Karina T Canadas; Samuel Kim; Milton Waner; Teresa O; Richard Antaya; Deepak Narayan Journal: Eplasty Date: 2019-04-16